BRPI0915837A2 - compostos antagonistas de rna para a inibição da expressão de glicerol-3-fosfato aciltransferase mitocondrial 1 (mtgpat1) - Google Patents

compostos antagonistas de rna para a inibição da expressão de glicerol-3-fosfato aciltransferase mitocondrial 1 (mtgpat1)

Info

Publication number
BRPI0915837A2
BRPI0915837A2 BRPI0915837A BRPI0915837A BRPI0915837A2 BR PI0915837 A2 BRPI0915837 A2 BR PI0915837A2 BR PI0915837 A BRPI0915837 A BR PI0915837A BR PI0915837 A BRPI0915837 A BR PI0915837A BR PI0915837 A2 BRPI0915837 A2 BR PI0915837A2
Authority
BR
Brazil
Prior art keywords
mtgpat1
inhibiting expression
antagonist compounds
phosphate acyltransferase
mitochondrial glycerol
Prior art date
Application number
BRPI0915837A
Other languages
English (en)
Portuguese (pt)
Inventor
Ellen Marie Straarup
Marie Lindholm
Original Assignee
Santaris Pharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santaris Pharma As filed Critical Santaris Pharma As
Publication of BRPI0915837A2 publication Critical patent/BRPI0915837A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y203/00—Acyltransferases (2.3)
    • C12Y203/01—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
    • C12Y203/01015—Glycerol-3-phosphate O-acyltransferase (2.3.1.15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
BRPI0915837A 2008-07-03 2009-06-24 compostos antagonistas de rna para a inibição da expressão de glicerol-3-fosfato aciltransferase mitocondrial 1 (mtgpat1) BRPI0915837A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7794208P 2008-07-03 2008-07-03
EP08104623 2008-07-03
PCT/EP2009/057907 WO2010000656A1 (en) 2008-07-03 2009-06-24 Rna antagonist compounds for the inhibition of expression of mitochondrial glycerol-3-phosphate acyltransferase 1 (mtgpat1)

Publications (1)

Publication Number Publication Date
BRPI0915837A2 true BRPI0915837A2 (pt) 2015-11-03

Family

ID=41066150

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0915837A BRPI0915837A2 (pt) 2008-07-03 2009-06-24 compostos antagonistas de rna para a inibição da expressão de glicerol-3-fosfato aciltransferase mitocondrial 1 (mtgpat1)

Country Status (11)

Country Link
US (1) US20120004276A1 (enExample)
EP (1) EP2310504A1 (enExample)
JP (1) JP2011526482A (enExample)
KR (1) KR20110031368A (enExample)
CN (1) CN102076854A (enExample)
AU (1) AU2009265836A1 (enExample)
BR (1) BRPI0915837A2 (enExample)
CA (1) CA2729897A1 (enExample)
EA (1) EA201170131A1 (enExample)
MX (1) MX2010013552A (enExample)
WO (1) WO2010000656A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101914309B1 (ko) * 2010-06-23 2018-11-02 큐알엔에이, 인크. 전압 작동 나트륨 통로, 알파 소단위(scna)에 대한 자연 안티센스 전사체의 저해에 의한 전압 작동 나트륨 통로, 알파 소단위(scna) 관련된 질환의 치료
EP2638163B1 (en) 2010-11-12 2017-05-17 The General Hospital Corporation Polycomb-associated non-coding rnas
US20140050728A1 (en) * 2011-01-28 2014-02-20 Board Of Regents Of The University Of Nebraska Methods and compositions for inhibiting cyclophilin d for the treatment and prevention of obesity and kidney indications
CN104583398A (zh) 2012-05-16 2015-04-29 Rana医疗有限公司 用于调节基因表达的组合物和方法
CA2889044A1 (en) 2012-11-15 2014-05-22 Roche Innovation Center Copenhagen A/S Anti apob antisense conjugate compounds
MX2015009056A (es) 2013-01-30 2015-10-05 Hoffmann La Roche Conjugados de oligonucleotidos de acido nucleico bloqueado y carbohidratos.
CN105039513B (zh) * 2015-05-29 2018-12-28 广州市第一人民医院 用于非酒精性脂肪肝相关目的基因多态性检测方法及其引物，以及试剂盒
CN104997768B (zh) * 2015-07-23 2017-11-17 上海市第六人民医院 鱼藤酮在制备降血糖药物中的应用
CN116075592A (zh) * 2020-06-09 2023-05-05 阿尔尼拉姆医药品有限公司 用于沉默gpam(线粒体甘油-3-磷酸酰基转移酶1)表达的sirna组合物和方法
GB202015056D0 (en) * 2020-09-23 2020-11-04 Cambridge Entpr Ltd Biomarkers
US12215322B2 (en) 2021-02-27 2025-02-04 Regeneron Pharmaceuticals, Inc. Treatment of liver disease with mitochondrial glycerol-3-phosphate acyltransferase (GPAM) inhibitors
EP4419682A2 (en) * 2021-10-22 2024-08-28 Amgen Inc. Rnai constructs for inhibiting gpam expression and methods of use thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002364900A1 (en) * 2001-11-30 2003-06-17 Bristol-Myers Squibb Company Polynucleotides encoding novel human mitochondrial and microsomal glycerol-3-phosphate acyl-transferases and variants thereof
US20050053981A1 (en) * 2003-09-09 2005-03-10 Swayze Eric E. Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini
US8178503B2 (en) * 2006-03-03 2012-05-15 International Business Machines Corporation Ribonucleic acid interference molecules and binding sites derived by analyzing intergenic and intronic regions of genomes

Also Published As

Publication number Publication date
EP2310504A1 (en) 2011-04-20
US20120004276A1 (en) 2012-01-05
JP2011526482A (ja) 2011-10-13
WO2010000656A1 (en) 2010-01-07
CN102076854A (zh) 2011-05-25
MX2010013552A (es) 2011-03-24
CA2729897A1 (en) 2010-01-07
KR20110031368A (ko) 2011-03-25
EA201170131A1 (ru) 2011-08-30
AU2009265836A1 (en) 2010-01-07

Similar Documents

Publication Publication Date Title
BRPI0915837A2 (pt) compostos antagonistas de rna para a inibição da expressão de glicerol-3-fosfato aciltransferase mitocondrial 1 (mtgpat1)
HUS1900029I1 (hu) Kináz inhibitor foszforszármazékok
BRPI0807626A2 (pt) Processo para a síntese de compostos de 2-aminotiazol como inibidores de quinase
EP2376425A4 (en) KINASE INHIBITORS COMPOUNDS
BRPI0816258A2 (pt) processo para a preparação de compostos úteis como inibidores de sglt
EP2120578A4 (en) KINASE INHIBITORS COMPOUNDS
BR112012002134A2 (pt) compostos inibidores de apaf-1
BRPI0918971A2 (pt) tienopirimidinas para composições farmacêuticas
BRPI0810452A2 (pt) Processo para a produção de composições de betume
BRPI0811156A2 (pt) compostos antagonistas de rna para a modulação de her3
BRPI0821129A2 (pt) Métodos para a inibição de cicatrização
EP2477498A4 (en) INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE
BRPI1009901A2 (pt) composição para inibição da formação de incrustação de cálcio
BRPI0920621A2 (pt) processos para síntese de composto macrolidos
EP2240962A4 (en) PROTECTION AGAINST ELECTROSTATIC DISCHARGE
DK2333107T3 (da) Genekspressionsprofil som markør for endometriel receptivitet
BR112012016178A2 (pt) inibidores de diacilglicerol aciltransferase
EP2169055A4 (en) NEW LYSOPHOSPHATIDATE ACYLTRANSFERASE GEN
BRPI0720097A2 (pt) Compostos de fosfonato
BRPI1013830A2 (pt) Processo para a iodação de compostos aromáticos
BRPI0909270A2 (pt) Compostos de sirna para inibição de rtp801
EP2300363A4 (en) BY BROM-SPONSORED SYNTHESIS OF FLUOROUS SULFUR COMPOUNDS
EP2276479A4 (en) PRODRUGS OF NEURAMINIDASE INHIBITORS
BR112012001586A2 (pt) Inibidores de fosfolipase d seletivos a isoforma
BRPI0817646A2 (pt) Processo para a descrição de um comportamento de um aparelho técnico

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]